JP2013505201A5 - - Google Patents

Download PDF

Info

Publication number
JP2013505201A5
JP2013505201A5 JP2012503432A JP2012503432A JP2013505201A5 JP 2013505201 A5 JP2013505201 A5 JP 2013505201A5 JP 2012503432 A JP2012503432 A JP 2012503432A JP 2012503432 A JP2012503432 A JP 2012503432A JP 2013505201 A5 JP2013505201 A5 JP 2013505201A5
Authority
JP
Japan
Prior art keywords
formulation
ligand
trl9
conjugate
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012503432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505201A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/001017 external-priority patent/WO2010114628A2/en
Publication of JP2013505201A publication Critical patent/JP2013505201A/ja
Publication of JP2013505201A5 publication Critical patent/JP2013505201A5/ja
Pending legal-status Critical Current

Links

Images

JP2012503432A 2009-04-03 2010-04-05 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物 Pending JP2013505201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16662509P 2009-04-03 2009-04-03
US61/166,625 2009-04-03
PCT/US2010/001017 WO2010114628A2 (en) 2009-04-03 2010-04-05 Formulation for inducing broadly reactive neutralizing anti-hiv antibodies

Publications (2)

Publication Number Publication Date
JP2013505201A JP2013505201A (ja) 2013-02-14
JP2013505201A5 true JP2013505201A5 (enExample) 2013-11-21

Family

ID=42828908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012503432A Pending JP2013505201A (ja) 2009-04-03 2010-04-05 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物

Country Status (6)

Country Link
US (1) US9402917B2 (enExample)
EP (1) EP2413951A4 (enExample)
JP (1) JP2013505201A (enExample)
AU (1) AU2010232915A1 (enExample)
CA (1) CA2757240A1 (enExample)
WO (1) WO2010114628A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235507B2 (en) 2005-04-12 2012-08-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
AU2008239628B2 (en) * 2007-04-13 2014-01-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20140322262A1 (en) * 2007-09-28 2014-10-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
JP2013505201A (ja) 2009-04-03 2013-02-14 デューク ユニバーシティー 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物
AU2011219025A1 (en) * 2010-02-25 2012-09-27 Duke University Method of inducing the production of protective anti-HIV-1 antibodies
US20140093556A1 (en) * 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
WO2014020205A2 (es) * 2012-07-31 2014-02-06 Universidad De Granada Inmunógenos anti-vih mejorados
CN118359733A (zh) * 2012-10-19 2024-07-19 昆士兰医学研究所理事会 改进的人类疱疹病毒免疫疗法
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
WO2024097957A1 (en) * 2022-11-03 2024-05-10 Duke University Novel antibodies for hiv and methods of making and using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1122576A (zh) 1993-03-11 1996-05-15 南加利福尼亚大学 免疫感染簇病毒感染的治疗策略
ATE246513T1 (de) 1993-05-27 2003-08-15 Entremed Inc Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
EP0750636A1 (en) 1994-03-14 1997-01-02 University Of Southern California Methods to diagnose and treat hiv-1 infection
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1250933A1 (en) 2001-04-17 2002-10-23 Istituto Superiore di Sanità Vaccines including as an adjuvant high dose type I IFN
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
JP2007524603A (ja) 2003-03-27 2007-08-30 ザ ユニバーシティー オブ テキサス Ｈｉｖ／エイズの受動免疫治療用ループス抗体
AU2006235507B2 (en) 2005-04-12 2012-08-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20080057075A1 (en) 2005-04-12 2008-03-06 Haynes Barton F Method of inducing neutralizing antibodies to human immunodeficiency virus
AU2008239628B2 (en) 2007-04-13 2014-01-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
TW200911304A (en) * 2007-05-24 2009-03-16 Glaxosmithkline Biolog Sa Lyophillised antigen composition
US20140322262A1 (en) 2007-09-28 2014-10-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20120070488A1 (en) 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2009111304A2 (en) 2008-02-29 2009-09-11 President And Fellows Of Harvard College A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
US8936789B2 (en) 2008-10-16 2015-01-20 New York Bood Center, Inc. Immunoenhancer-linked oligomeric HIV envelope peptides
JP2013505201A (ja) 2009-04-03 2013-02-14 デューク ユニバーシティー 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物
JP2012528790A (ja) 2009-04-03 2012-11-15 デューク ユニバーシティー 配合物

Similar Documents

Publication Publication Date Title
JP2013505201A5 (enExample)
Azmi et al. Recent progress in adjuvant discovery for peptide-based subunit vaccines
JP2016513638A5 (enExample)
RU2014136401A (ru) Композиции neisseria meningitidis и способы их применения
JP2009510133A5 (enExample)
RU2010107207A (ru) Новые синтетические агонисты tlr9
WO2007099446A3 (en) Virosome-like vesicles comprising gp41-derived antigens
EP2281573A3 (en) Influenza vaccine formulations for intradermal delivery
JP2016502551A5 (enExample)
JP2012522802A5 (enExample)
WO2012051211A3 (en) Antigen delivery platforms
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
CA2523032A1 (en) Vaccines for cancer therapy
RU2017129340A (ru) Композиции nеisseria мeningitidis и способы их получения
WO2010114628A3 (en) Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
JP2008539252A5 (enExample)
MX341775B (es) Vectores para vacunas y metodos para potenciar respuestas inmunes.
WO2011000962A3 (en) Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
Serrano et al. Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design
WO2013082535A3 (en) Controlled-release peptide compositions and uses thereof
JP2010523676A5 (enExample)
JP2010506926A5 (enExample)
FR2932681B1 (fr) Peptides immunogenes issus de la proteine midkine comme vaccin anticancereux
WO2014179184A8 (en) Compositions for inducing immune tolerance to coagulation factor proteins